Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

Purpose: Successful implementation of genomic testing in clinical practice is critical for
identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible …

Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …

Abstract Purpose: The phase III PROfound study (NCT02987543) evaluated olaparib versus
abiraterone or enzalutamide (control) in metastatic castration-resistant prostate cancer …

Despite recent therapeutic advances, castration‐resistant prostate cancer (CRPC) remains a
lethal disease and novel therapies are needed. Precision oncology provides an avenue for …

Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …

Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with
metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or …

Deleterious aberrations in DNA repair genes are actionable in approximately 25% of
metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination …

Prostate cancer is a disease with significant interpatient genomics, with a proportion of
patients presenting mutations in key homologous recombination repair (HRR) gene …